Holland Capital has sold its portfolio company Inno4Life, a manufacturer of machines for the pharmaceutical industry, to Dec Group, a Swiss powder handling and process containment equipment provider.
Inno4Life’s management will remain actively involved in the company after its acquisition, which will continue to operate under its own name following the deal.
Inno4Life is a manufacturer of complex filling and packaging machines for the pharmaceutical industry. The company delivers tailor-made solutions to its customers, which include large pharmaceutical companies.
Inno4Life searched for a strong partner to team up with in order to enable further international growth, and found this partner in Dec Group. “Dec’s acquisition provides a major growth opportunity for both our businesses through an enhanced service offering for our clients. We will be best positioned to offer outstanding quality solutions and increased effectiveness as a result of combined action and co-operation,” Johan Klootwijk, co-founder and managing director of Inno4Life, commented on the deal.
Jan-Frens van Giessel, healthcare partner at Holland Capital, is also pleased with the acquisition: “Inno4Life has gained a strong position within the pharmaceutical industry. The acquisition by Dec is a logical next step that enables Inno4Life to continue their international expansion.”
Focusing on healthcare and tech, and investing 90 percent in Dutch companies, the Amsterdam-based private equity firm has exited more than 140 companies to date. Holland Capital’s previous exits include Dutch Sec, Highcare and Karify.